Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 12/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 8/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1934601 | 0.91 | SCN9A (0.49) | SCN9AKCNH2SCN5AAURKA | |
| SCHEMBL1935790 | 0.82 | ROCK1 (0.51) | SCN9AKCNH2AURKA | |
| SCHEMBL1936378 | 0.76 | SCN9A (0.51) | SCN9AKCNH2SCN5AKDRAURKA | |
| SCHEMBL2281702 | 0.75 | IKBKB (0.46) | CDK1AURKA | |
| SCHEMBL12354928 | 0.75 | IGF1R (0.49) | SCN9AKCNH2SCN5A | |
| SCHEMBL12346572 | 0.74 | SCN9A (0.60) | SCN9AKCNH2SCN5ASYK | |
| SCHEMBL3226666 | 0.73 | SCN9A (0.54) | SCN9AKCNH2SCN5ACDK1AURKA | |
| SCHEMBL1845384 | 0.73 | MEN1 (0.46) | — | |
| SCHEMBL7167652 | 0.73 | MAPT (0.37) | — | |
| SCHEMBL12354945 | 0.72 | IGF1R (0.49) | SCN9AKCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2331518-A1 | NEW BRADYKININ B1 ANTAGONISTS | Evotec AG (DE) | 2011-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | SCN9A 1091/4885KCNH2 156/4885SCN5A 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.